Integration of Endocrine Therapy with Targeted Agents

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2009 Jan 9

PMID 19128434

Citations 3

Authors

Stephen R D Johnston

Affiliations

Soon will be listed here.

Citing Articles

Optimizing the use of neoadjuvant endocrine therapy.

Agrawal L, Mayer I Curr Oncol Rep. 2015; 17(7):33.

PMID: 26008918 PMC: 5524371. DOI: 10.1007/s11912-015-0455-z.

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.

Frampton J Drugs. 2009; 69(15):2125-48.

PMID: 19791830 DOI: 10.2165/11203240-000000000-00000.

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?.

Ingle J Breast Cancer Res. 2009; 10 Suppl 4:S15.

PMID: 19128428 PMC: 2614841. DOI: 10.1186/bcr2175.

References

Lipton A, Ali S, Leitzel K, Demers L, Harvey H, Chaudri-Ross H . Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003; 21(10):1967-72. DOI: 10.1200/JCO.2003.09.098. View

Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A . Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res. 2006; 8(1):R4. PMC: 1413988. DOI: 10.1186/bcr1366. View

Massarweh S, Osborne C, Jiang S, Wakeling A, Rimawi M, Mohsin S . Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006; 66(16):8266-73. DOI: 10.1158/0008-5472.CAN-05-4045. View

Jelovac D, Macedo L, Goloubeva O, Handratta V, Brodie A . Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005; 65(12):5439-44. DOI: 10.1158/0008-5472.CAN-04-2782. View

Ingle J, Suman V, Rowland K, Mirchandani D, Bernath A, Camoriano J . Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006; 24(7):1052-6. DOI: 10.1200/JCO.2005.04.1053. View

Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H . Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2006; 18(1):64-69. DOI: 10.1093/annonc/mdl341. View

Shou J, Massarweh S, Osborne C, Wakeling A, Ali S, Weiss H . Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96(12):926-35. DOI: 10.1093/jnci/djh166. View

Steger G, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U . Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer. 2005; 41(17):2655-61. DOI: 10.1016/j.ejca.2005.07.016. View

Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z . Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7(5):R609-16. PMC: 1242128. DOI: 10.1186/bcr1262. View

10.

Osipo C, Gajdos C, Liu H, Chen B, Jordan V . Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003; 95(21):1597-608. DOI: 10.1093/jnci/djg079. View

11.

Johnston S, Leary A, Martin L, Smith I, Dowsett M . Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?. Cancer. 2007; 112(3 Suppl):710-717. DOI: 10.1002/cncr.23190. View

12.

Dauvois S, White R, Parker M . The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993; 106 ( Pt 4):1377-88. DOI: 10.1242/jcs.106.4.1377. View

13.

Martin L, Pancholi S, Chan C, Farmer I, Kimberley C, Dowsett M . The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer. 2005; 12(4):1017-36. DOI: 10.1677/erc.1.00905. View

14.

Bachman K, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S . The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004; 3(8):772-5. DOI: 10.4161/cbt.3.8.994. View

15.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M . Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26(10):1664-70. DOI: 10.1200/JCO.2007.13.5822. View

16.

Marcom P, Isaacs C, Harris L, Wong Z, Kommarreddy A, Novielli N . The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2006; 102(1):43-9. DOI: 10.1007/s10549-006-9307-8. View

17.

Chu I, Blackwell K, Chen S, Slingerland J . The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005; 65(1):18-25. View

18.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L . A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006; 103(20):7795-800. PMC: 1472524. DOI: 10.1073/pnas.0602468103. View

19.

Oh A, Lorant L, Holloway J, Miller D, Kern F, El-Ashry D . Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol. 2001; 15(8):1344-59. DOI: 10.1210/mend.15.8.0678. View

20.

Osborne C, Hilsenbeck S, McCue B, Wakeling A, McClelland R, Manning D . Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995; 87(10):746-50. DOI: 10.1093/jnci/87.10.746. View